SCHEMBL1967538

SCHEMBL1967538

CCCCn1c(=O)c(C(=O)OCC)c(O)c2cccn21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
LMNA P02545 3/20 0.63
ALDH1A1 P00352 9/20 0.58
HTT P42858 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RECQL P46063 1/20 0.47
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
PABPC1 P11940 1/20 0.42
HPGD P15428 4/20 0.42
USP2 O75604 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965306 0.95 ALDH1A1 (0.64) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL3761069 0.86 ALDH1A1 (0.51) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL1967350 0.82 KDM4E (0.54) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL1967127 0.81 KDM4E (0.48) KDM4ELMNAALDH1A1HTTRECQL
SCHEMBL1965910 0.80 ALDH1A1 (0.47) KDM4ELMNAALDH1A1HTTL3MBTL1
SCHEMBL1966882 0.80 ALDH1A1 (0.46) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL1966096 0.79 FEN1 (0.53) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL1965997 0.79 KDM4E (0.50) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL1968107 0.79 KDM4E (0.50) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL1969780 0.78 POLB (0.51) KDM4ELMNAALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 KDM4E 471/4885LMNA 3079/4885ALDH1A1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.